Viking Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St futures slip as oil surge puts markets on edge
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Citi Starts Viking Therapeutic (VKTX) at Neutral
February 7, 2025 6:52 AM ESTCiti analyst David Lebowitz initiates coverage on Viking Therapeutic (NASDAQ: VKTX) with a Neutral rating and a price target of $38.00.
The analyst comments "The relatively recent emergence of GLP-1s for the treatment of obesity has rapidly established a megamarket opportunity... More
Viking Therapeutic (VKTX) PT Lowered to $95 at Truist Securities
February 6, 2025 12:07 PM ESTTruist Securities analyst Joon Lee lowered the price target on Viking Therapeutic (NASDAQ: VKTX) to $95.00 (from $120.00) while maintaining a Buy rating.
The analyst comments "4Q24 update narrowed timeline for the start of 2x Ph3 studies of SQVK2735 in obesity. Toplines from Ph3... More
